- About Us
- Nano-Social Network
- Nano Consulting
- My Account
February 8th, 2005
Flamel Technologies announced today that it has posted a summary of Phase IIa data conducted on Flamel's long-acting insulin, Basulin®, on its website.
"We are pleased with the results of the Phase IIa obtained on thirty (30) Type I diabetic patients. This study confirms our strong expectations for Basulin® because Medusa®, our nano-particulate system, is the only one capable to delivery human insulin with this level of efficacy," said Dr. Gerard Soula.
|Related News Press|
Tiny nanoclusters could solve big problems for lithium-ion batteries February 21st, 2017
Breakthrough with a chain of gold atoms: In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport February 20th, 2017
In-cell molecular sieve from protein crystal February 14th, 2017
Particle Works creates range of high performance quantum dots February 23rd, 2017
GLOBALFOUNDRIES Announces Availability of 45nm RF SOI to Advance 5G Mobile Communications: Optimized RF features deliver high-performance solutions for mmWave beam forming applications in 5G smartphones and base stations February 22nd, 2017